GECO PERU – Contact Details
Country
Peru
Chair
Dr C.V. Sologuren, Instituto Nacional de Enfermedades Neoplásicas, Av. Angamos Este 2520, LIMA 34, PERU. Tel: +51 1 710 6900 Fax: +51 1 272 0309 Email: [email protected]
Contact Person
Dr H. Gomez, Research Division, Instituto Nacional de Enfermedades Neoplásicas, Av. Angamos Este 2520, LIMA 34, PERU. Tel: +51 1 710 6900 Fax: +51 1 271 1226 Email: [email protected]
Website
GECO PERU – Study Details
Title
Determination of prognostic factors in the outcome to a metronomic treatment with low doses of cyclophosphamide and methotrexate in patients with advanced breast cancer.
Coordinator(s)
Dr K. Robles, Email: [email protected]
Summary
- Most patients with advanced breast cancer have increased levels of VEGF (vascular endothelial growth factor) over those with local disease. The VEGF in the cytoplasm of the tumor cells is a predictive factor for overall survival and progression free survival.
- M. Colleoni et al., reported a study of 64 patients with previous treatment with chemotherapy for advanced breast cancer and indicated that patients who were treated with low doses of methotrexate and cyclophosphamide showed objective responses in 19%, with overall response of 31.7%.
Scheme
Update
- Proposed study
Related Publications
Colleoni M. Rocca A, Sandri Mt et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13:73–80.
Colleoni M, Orlando L, Sanna G et al. Metronomic low-dose oral cyclophosphamide and methotrexatte plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Annals of Oncology 2006; 17: 232–238.
MacKenzie KL, Lock RB. An endothelial metronome breast cancer? Blood 2006; 108: 407–408.
Topics
- Metronomic chemotheraphy
- Metastatic breast cancer
Keywords
Angiogenesis
